Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma
Recruiting now · Not applicable
Conditions studied: Melasma, Facial Melasma
In brief
Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable. This randomized split-face interventional study aims to compare the efficacy and safety of injectable platelet-rich fibrin (i-PRF) versus intradermal tranexamic acid (TA) in the treatment of facial melasma. Adult female patients with bilateral symmetrical facial melasma will be enrolled. In each participant, one side of the face will be randomly assigned to receive i-PRF and the contralateral side will receive intradermal TA. Patients will undergo five treatment sessions at 2-week intervals. Clinical response will be assessed using the modified Melasma Area and Severity Index (mMASI), Antera 3D camera measurements, Physician Global Assessment, patient satisfaction, and Melasma Quality of Life (MelasQoL) questionnaire. Safety will be evaluated by recording adverse events such as pain, tenderness, erythema, swelling, infection, ecchymosis, and hematoma. The study is designed to determine whether i-PRF is an effective and safe treatment option for melasma compared with intradermal tranexamic acid.
Key facts
- Study ID
- NCT07540702
- Run by
- Kasr El Aini Hospital
- People needed
- 21
- Starts
- 2026-02-01
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-04-22
Who can join
Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)
- Female participants aged 18 to 50 years
- Fitzpatrick skin types III to IV
- Mild to moderate facial melasma
- No melasma-specific treatment within the previous 4 weeks
- No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months
- Willing and able to provide written informed consent and comply with study procedures
You may not qualify if…
- Pregnancy or lactation
- Bleeding or coagulation disorders
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception
- Active skin infection or facial inflammation
- History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo
- Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease
Where it is running
- Kasr El Aini Hospital — Cairo, Cairo Governorate, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.